Download presentation
Presentation is loading. Please wait.
Published by蝙放 燕 Modified over 6 years ago
3
Current Dyslipidemia Management Guidelines
4
Residual Risk
5
PCSK9 and Hypercholesterolemia
6
PCSK9 Inhibitors Monoclonal Antibodies
7
Dramatic LDL-C Lowering Who Will Benefit Most?
8
Alirocumab Trials ODYSSEY FH I and FH II Studies
9
FH I and FH II Baseline Characteristics
10
FH I and FH II Results at W24
11
FH I and FH II Results Over 52 Weeks
12
FH I and FH II Percentage Reaching LDL-C Goals at W24
13
Looking Ahead
14
ODYSSEY Combo II Study
15
Combo II Baseline Characteristics
16
Combo II Results Over 52 Weeks
17
FH I, FH II, Combo II AEs Occurring in ≥ 5% of Patients
18
Take-home Messages From FH I/II and Combo II
19
ODYSSEY Long-term Study Design
20
ODYSSEY Long-term Study AE
21
ODYSSEY Long-term Study TEAEs
22
ODYSSEY Long-term Study LDL-C Reduction
23
ODYSSEY Long-term Study CV Death
24
Trials of Other PCSK9 Inhibitors
25
Ongoing Trials of PCSK-9 Inhibitors CV Outcomes
26
PCSK-9 Inhibitors The Path to Clinical Practice
27
Abbreviations
28
Abbreviations (cont)
29
Abbreviations (cont)
30
Abbreviations (cont)
31
References
32
References (cont)
33
References (cont)
34
References (cont)
35
References (cont)
36
References (cont)
37
References (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.